Gout

BMJ Clin Evid. 2008 Nov 17:2008:1120.

Abstract

Introduction: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for acute gout? What are the effects of treatments to prevent gout in people with prior acute episodes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 21 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: colchicine, corticosteroids, corticotrophin (ACTH), non-steroidal anti-inflammatory drugs (NSAIDs), sulfinpyrazone, xanthine oxidase inhibitors, advice to lose weight, advice to reduce alcohol intake, advice to reduce dietary intake of purines.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Acute Disease
  • Adrenocorticotropic Hormone / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Colchicine / therapeutic use
  • Gout Suppressants* / therapeutic use
  • Gout* / drug therapy
  • Humans

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Gout Suppressants
  • Adrenocorticotropic Hormone
  • Colchicine